What it's for (Indications)
- Treatment of Amoebic Dysentery, hepatic amoebiasis, bacterial vaginosis (in female patients 12 years of age and older), and trichomoniasis (in patients 12 years of age and older).
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For bacterial vaginosis (female patients 12 years and older) and trichomoniasis (patients 12 years and older): Administer a single 2-gram packet of granules once orally. For trichomoniasis, treat sexual partners with the same dose and at the same time. The entire contents of the packet should be sprinkled onto applesauce, yogurt, or pudding and consumed within 30 minutes without chewing or crunching the granules. A glass of water may be taken afterward. Do not dissolve SOLOSEC in any liquid. |
Safety & Warnings
Common Side Effects
- Common adverse reactions include vulvovaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus.
- It should not be taken by pregnant or breastfeeding women.
- Patients should avoid driving as it may affect their ability.
Serious Warnings
- Black Box Warning: None
- Not recommended during pregnancy or lactation due to potential risks.
- Patients should exercise caution when driving.
- There is a risk of vulvovaginal candidiasis.
- Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole (another nitroimidazole drug) in patients with Cockayne syndrome, a potential risk to consider with secnidazole due to its structural relation.
How it Works (Mechanism of Action)
Secnidazole, a prominent member of the 5-nitroimidazole class of antimicrobial agents, exerts its potent therapeutic effects primarily through a well-defined intracellular reductive activation process. As a prodrug, secnidazole must be metabolically activated within susceptible anaerobic bacteria and parasitic protozoa. This activation is mediated by intracellular electron-transport proteins, such as ferredoxins, which are present in these microorganisms and possess uniquely low redox potentials. Upon reduction, secnidazole is transformed into highly reactive cytotoxic intermediates, including free radicals and other reduced nitrogen compounds. These highly unstable and reactive species then covalently bind to and extensively damage the microbial DNA. This destructive interaction leads to the disruption of the DNA helix structure, inhibition of crucial DNA synthesis pathways, and ultimately results in the fragmentation and degradation of the microorganism's genetic material. Beyond DNA damage, these cytotoxic metabolites can also interfere with other vital cellular processes, including protein synthesis, by compromising essential enzymes and cellular components. The cumulative impact of DNA damage and widespread metabolic disruption culminates in the death of the targeted anaerobic bacteria and protozoa, thus exhibiting a powerful bactericidal and protozoacidal action. This mechanism is selectively toxic, as aerobic host cells generally lack the specific low-redox potential enzymatic systems required to activate the nitroimidazole prodrug into its cytotoxic form, thereby preserving host cell integrity.